BMJ Open Diabetes Research & Care-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2269516, encodeId=3458226951623, content=2024.10.16投稿 2025.2.1收到2名审稿人意见（1人支持/1人拒稿） 状态回退 2025.2.20追加第3名审稿人 2025.3.1录用 总耗时136天，太不容意了，说起来全是心酸泪。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 17:36:03 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0 经验分享：审稿3轮，历时6个月发表。RCT。本来想>5，2020年<4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;内分泌;T2DM 经验分享：官方自己的数据： Acceptance rate 58% Mean time from submission to first decision for all papers 32 days Mean time from submission to first decision for reviewed papers 41 days Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]

2025-06-15 ms6000002977722166 来自上海

2024.10.16投稿
2025.2.1收到2名审稿人意见（1人支持/1人拒稿）
状态回退
2025.2.20追加第3名审稿人
2025.3.1录用
总耗时136天，太不容意了，说起来全是心酸泪。

0 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2269516, encodeId=3458226951623, content=2024.10.16投稿 2025.2.1收到2名审稿人意见（1人支持/1人拒稿） 状态回退 2025.2.20追加第3名审稿人 2025.3.1录用 总耗时136天，太不容意了，说起来全是心酸泪。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 17:36:03 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0 经验分享：审稿3轮，历时6个月发表。RCT。本来想>5，2020年<4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;内分泌;T2DM 经验分享：官方自己的数据： Acceptance rate 58% Mean time from submission to first decision for all papers 32 days Mean time from submission to first decision for reviewed papers 41 days Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]

2023-02-02 ms2145678728954567 来自江苏省

投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection

130 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2269516, encodeId=3458226951623, content=2024.10.16投稿 2025.2.1收到2名审稿人意见（1人支持/1人拒稿） 状态回退 2025.2.20追加第3名审稿人 2025.3.1录用 总耗时136天，太不容意了，说起来全是心酸泪。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 17:36:03 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0 经验分享：审稿3轮，历时6个月发表。RCT。本来想>5，2020年<4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;内分泌;T2DM 经验分享：官方自己的数据： Acceptance rate 58% Mean time from submission to first decision for all papers 32 days Mean time from submission to first decision for reviewed papers 41 days Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]

2022-10-23 ms7000000324097631

来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受返修一件很中肯，投稿速度已经算快了，感恩🙏

136 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2269516, encodeId=3458226951623, content=2024.10.16投稿 2025.2.1收到2名审稿人意见（1人支持/1人拒稿） 状态回退 2025.2.20追加第3名审稿人 2025.3.1录用 总耗时136天，太不容意了，说起来全是心酸泪。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 17:36:03 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0 经验分享：审稿3轮，历时6个月发表。RCT。本来想>5，2020年<4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;内分泌;T2DM 经验分享：官方自己的数据： Acceptance rate 58% Mean time from submission to first decision for all papers 32 days Mean time from submission to first decision for reviewed papers 41 days Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]

2020-10-02 1df0083fm15(暂无匿称)

审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0
经验分享：审稿3轮，历时6个月发表。RCT。本来想>5，2020年<4，不过有前景。主编曾获ADA大奖。

255 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2269516, encodeId=3458226951623, content=2024.10.16投稿 2025.2.1收到2名审稿人意见（1人支持/1人拒稿） 状态回退 2025.2.20追加第3名审稿人 2025.3.1录用 总耗时136天，太不容意了，说起来全是心酸泪。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 17:36:03 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0 经验分享：审稿3轮，历时6个月发表。RCT。本来想>5，2020年<4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;内分泌;T2DM 经验分享：官方自己的数据： Acceptance rate 58% Mean time from submission to first decision for all papers 32 days Mean time from submission to first decision for reviewed papers 41 days Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]

2019-11-28 hpchensd

有在这杂志投稿的么

278 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2269516, encodeId=3458226951623, content=2024.10.16投稿 2025.2.1收到2名审稿人意见（1人支持/1人拒稿） 状态回退 2025.2.20追加第3名审稿人 2025.3.1录用 总耗时136天，太不容意了，说起来全是心酸泪。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 17:36:03 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0 经验分享：审稿3轮，历时6个月发表。RCT。本来想>5，2020年<4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;内分泌;T2DM 经验分享：官方自己的数据： Acceptance rate 58% Mean time from submission to first decision for all papers 32 days Mean time from submission to first decision for reviewed papers 41 days Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]

2020-06-02 lovetcm

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：糖尿病;内分泌;T2DM
经验分享：官方自己的数据：
Acceptance rate 58%
Mean time from submission to first decision for all papers 32 days
Mean time from submission to first decision for reviewed papers 41 days
Mean time from acceptance to publication 26 days

252 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2269516, encodeId=3458226951623, content=2024.10.16投稿 2025.2.1收到2名审稿人意见（1人支持/1人拒稿） 状态回退 2025.2.20追加第3名审稿人 2025.3.1录用 总耗时136天，太不容意了，说起来全是心酸泪。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 17:36:03 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0 经验分享：审稿3轮，历时6个月发表。RCT。本来想>5，2020年<4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;内分泌;T2DM 经验分享：官方自己的数据： Acceptance rate 58% Mean time from submission to first decision for all papers 32 days Mean time from submission to first decision for reviewed papers 41 days Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]

2020-03-08 Omega 3

审稿速度:6.0 | 投稿命中率:25.0
经验分享：审稿速度比较慢。

268 0 举报

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务